Abstract: The present disclosure relates to a pharmaceutical composition for use in preventing or treating retinal or macular diseases, the composition comprising: a polypeptide comprising an amino acid sequence with at least 70% sequence identity with that of TAFA protein (e.g., TAFA1 to TAFA4); a nucleic acid encoding the polypeptide; a vector comprising the nucleic acid, a recombinant virus particle comprising the vector and capsid protein; or a cell comprising the nucleic acid or vector. In addition, the present disclosure relates to an adeno-associated virus (AAV) vector that comprises a nucleic acid encoding a polypeptide having an amino acid sequence with at least 70% sequence identity with that of TAFA protein, and a recombinant virus particle containing the AAV vector and capsid protein.

Abstract: The present disclosure provides adeno-associated virus (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.

Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.

Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.

Abstract: The present disclosure provides a pharmaceutical composition for preventing or treating a variety of diseases through c-Met activation in cells induced by the anti-c-Met antibody described herein which functions as a c-Met agonist. The current invention concerns a method for preventing or treating various diseases through c-Met activation by the anti-c-Met antibody described herein.

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

Abstract: The present disclosure provides a pharmaceutical composition for preventing or treating a variety of diseases through c-Met activation in cells induced by the anti-c-Met antibody described herein which functions as a c-Met agonist. The current invention concerns a method for preventing or treating various diseases through c-Met activation by the anti-c-Met antibody described herein.